Uğur Özkerim· @UOzkerim · X·· 1 天前评分70
正文 · 原文
🚨 Another important Phase III trial at #ESMO26!
#SAFFRON: Osimertinib + savolitinib vs chemotherapy in EGFR-mutant, MET-high NSCLC after osimertinib.
📊 PFS: 7.6 vs 5.4 months
📊 OS: 17.8 vs 12.9 months
Both PFS and OS significantly improved!
A promising new targeted treatment option, highlighting the importance of biomarker testing after progression.
#LungCancer
@OncoAlert @StephenVLiu @GlopesMd @ManuelDomine @weoncologists @OpenMedKate
21 浏览 · 0 赞 · 0 转发 · 0 回复
来源：Uğur Özkerim · x.com